1
|
Meyer P, Biston MC, Khamphan C, Marghani T, Mazurier J, Bodez V, Fezzani L, Rigaud PA, Sidorski G, Simon L, Robert C. Automation in radiotherapy treatment planning: Examples of use in clinical practice and future trends for a complete automated workflow. Cancer Radiother 2021; 25:617-622. [PMID: 34175222 DOI: 10.1016/j.canrad.2021.06.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 06/04/2021] [Indexed: 01/19/2023]
Abstract
Modern radiotherapy treatment planning is a complex and time-consuming process that requires the skills of experienced users to obtain quality plans. Since the early 2000s, the automation of this planning process has become an important research topic in radiotherapy. Today, the first commercial automated treatment planning solutions are available and implemented in a growing number of clinical radiotherapy departments. It should be noted that these various commercial solutions are based on very different methods, implying a daily practice that varies from one center to another. It is likely that this change in planning practices is still in its infancy. Indeed, the rise of artificial intelligence methods, based in particular on deep learning, has recently revived research interest in this subject. The numerous articles currently being published announce a lasting and profound transformation of radiotherapy planning practices in the years to come. From this perspective, an evolution of initial training for clinical teams and the drafting of new quality assurance recommendations is desirable.
Collapse
Affiliation(s)
- P Meyer
- Department of radiotherapy, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France; ICUBE, CNRS UMR 7357, team IMAGES, Strasbourg, France.
| | - M-C Biston
- Department of radiotherapy, Centre Léon Bérard (CLB), Lyon, France; CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, Villeurbanne, France
| | - C Khamphan
- Department of medical physics, Institut du Cancer Avignon-Provence, Avignon, France
| | - T Marghani
- Institut de radiothérapie Amethyst du Sud de l'Oise, Creil, France
| | - J Mazurier
- Centre de radiothérapie Oncorad Garonne, Toulouse, France
| | - V Bodez
- Department of medical physics, Institut du Cancer Avignon-Provence, Avignon, France
| | - L Fezzani
- Institut de radiothérapie Amethyst du Sud de l'Oise, Creil, France
| | - P A Rigaud
- Institut de radiothérapie Amethyst du Sud de l'Oise, Creil, France
| | - G Sidorski
- Centre de radiothérapie Oncorad Garonne, Toulouse, France
| | - L Simon
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France; Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM U1037, Toulouse, France
| | - C Robert
- Université Paris-Saclay, Institut Gustave Roussy, INSERM, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France; Department of Radiotherapy, Gustave Roussy, Villejuif, France
| |
Collapse
|